Drug Development

Zomig proves effective in acute treatment of cluster headache

Published in Health and Medicine Week, October 10th, 2005

Zolmitriptan (Zomig) nasal spray is highly effective and well tolerated in the acute treatment of cluster headache, an extremely severe form of headache pain also known as suicide headache due to the excruciating pain it causes.

This was the conclusion of data presented for the first time at the European Federation of Neurological Societies (EFNS) annual congress.

A new clinical study shows that zolmitriptan nasal spray (ZNS) achieved the primary endpoint of headache relief at 30 minutes with significantly higher response compared to placebo (60% ZNS 10mg, 38% ZNS 5mg vs. 21% placebo; p<0.001),(1) demonstrating a reduction from moderate, severe or...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health and Medicine Week

Source: Health and Medicine Week (2005-10-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry